In addition, and in order to evaluate the prognostic potential of CEA specific glycosylation, we assessed the expression of both CEA and SLex directly in gastric cancer tissues and evaluated this CEA-SLex conjoint signature with the respective clinicopathological characteristics. The gene discussed is CEACAM5; the disease is gastric cancer.